BridgeMD
New treatment option for Emotional Processing
Official title 7T Amygdala and Citalopram Study
ClinicalTrials.gov ID: NCT06412315
What this study is testing
What is Citalopram?
Citalopram is an investigational medicine, given as a pill taken by mouth, being studied as a potential treatment for emotional processing.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The goal of this study is to investigate how a common antidepressant citalopram (which increases the levels of the chemical messenger serotonin), affects how a key area of the brain involved in depression (the amygdala) responds to emotional information. Healthy participants will undergo medical and psychiatric health screening, after which they will be assigned to receive either a single dose of citalopram (20mg) or placebo, and undergo brain scanning (7T fMRI) whilst viewing emotional faces.
- You might receive a placebo (an inactive treatment) instead of the study drug.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 40. Healthy volunteers may be eligible.
You may be able to join if
- Participant is willing and able to give informed consent for participation in the research
- Sufficiently fluent English to understand and complete the task
You likely can't join if
- Participants with ferromagnetic objects in their bodies (e.g. metal implants, vessel clips, shrapnel injuries) or with implanted devices which may be...
- Any other MRI contraindication following MRI safety screening
- History or current significant psychiatric illness (like major depressive disorder)
- Current or past diagnosis of any significant personality disorder (e.g. borderline personality disorder) according to self-report
- Diagnosis of attention deficit hyperactive disorder or autistic spectrum disorder that impairs daily functioning, requires pharmacotherapy or in the...
- Currently or within last 3 months taking psychoactive medications (requires further discussion with researcher)
See the full eligibility criteria
- Participant is willing and able to give informed consent for participation in the research
- Sufficiently fluent English to understand and complete the task
- Participants with ferromagnetic objects in their bodies (e.g. metal implants, vessel clips, shrapnel injuries) or with implanted devices which may be damaged by the magnet (e.g. heart pacemakers)
- Any other MRI contraindication following MRI safety screening
- History or current significant psychiatric illness (like major depressive disorder)
- Current or past diagnosis of any significant personality disorder (e.g. borderline personality disorder) according to self-report
- Diagnosis of attention deficit hyperactive disorder or autistic spectrum disorder that impairs daily functioning, requires pharmacotherapy or in the opinion of the study medic would affect the scientific integrity of...
- Currently or within last 3 months taking psychoactive medications (requires further discussion with researcher)
- Current or within the last 3 months use of medication that might interact with the effects of citalopram or affect the scientific integrity of the study
- Known contraindication to citalopram including: past allergic reaction to citalopram or any other medicines, diagnosis of a cardiovascular condition, glaucoma, type 1 or type 2 diabetes, diagnosis of epilepsy, previous...
- Any other current or past medical conditions which in the opinion of the study medic may interfere with the safety of the participant or the scientific integrity of the study including epilepsy/seizures, brain injury...
- Clinically significant abnormal values for urine drug screen, pulse, and blood pressure measurement (in accordance with Best Practice Guidance 13: 'Non-invasive measurement of blood pressure'). A participant with a...
- Current alcohol or substance misuse disorder
- Body Mass Index under 18 and over 30
- Pregnant or planning a pregnancy, or breast feeding
- Previously taken part in a study that used similar computer tasks (MRI faces task, emotional test battery) as those in the present study
- Participation in a study that involves the use of a psychoactive medication or brain stimulation within the last three months
- Use of recreational drugs (e.g. cannabis, cocaine, amphetamines) within last three months
- Smoking \> 5 cigarettes per day, or vape a comparable amount (\> 0.5ml / a quarter of a 2ml vape);
- Typically drinks \> 6 caffeinated drinks per day (e.g. tea, coffee, coca cola, Red Bull)
- Participant is unlikely to comply with the clinical study protocol or is unsuitable for any other reason, in the opinion of the Investigator
The study team makes the final eligibility decision.
Where it's taking place
- Oxford, Oxfordshire, United Kingdom
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 40 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Oxford, Oxfordshire, United Kingdom. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.